Skip to content

Prognosis Value of Bioimpedance Analysis (BIA) Phase Angle at Admission in Intensive Care Unit (ICU) Patients

PHASE ANGLE PROJECT

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01907347
Acronym
PAP
Enrollment
1000
Registered
2013-07-24
Start date
2013-03-01
Completion date
2014-08-31
Last updated
2017-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit Patients

Keywords

intensive care unit (ICU), body composition, phase angle, mortality, nosocomial infection, bioimpedance analysis, nutrition

Brief summary

Critically ill patients feature a loss of fat-free mass (FFM) up to 440 g/day, which is associated with increased morbidity and prolonged recovery. In several clinical conditions, FFM or phase angle (PhA)derived from BIA have been associated with clinical outcome. However, solid data to support this association in ICU patients are lacking. Only one retrospective study of 51 ICU patients with acute respiratory failure correlated loss of active cell mass with mortality. In a pilot study performed in 55 ICU patients, the investigators observed that five kHz BIA PhA was significantly related to SOFA (r=0.38, P=0.03). The relation between PhA and mortality remains to be determined in ICU patients. Classic ICU validated severity scores (e.g. Acute Physiology and Chronic Health Evaluation (APACHE), Sequential Organ Failure Assessment (SOFA), Simplified Acute Physiology Score (SAPS)) and recent nutritional scores have been developed to foresee the clinical outcome of ICU patients. Most of these scores are time consuming and suffer some degree of discriminative power (i.e. APACHE II and SAPS II are not validated in cardiovascular surgery patients). PhA is reflecting intracellular status: altered intracellular water (ICW) to extracellular water (ECW) distribution is suggested by low PhA. PhA measurement does not require anamnestic parameters, body weight, and lab tests. It could easily, accurately and repeatedly measured at bedside. PhA has been correlated with the disease prognosis in HIV infection, hemodialysis, peritoneal dialysis, chronic renal failure and liver cirrhosis patients. These studies suggest that PhA may be useful in determining increased risk of morbidity in the ICU. Computerized tomography (CT) images targeted on the 3rd lumbar vertebrae (L3) could accurately measure FFM13 and predict survival in cancer patients. Body composition evaluation by CT presents great practical significance due to its routine ICU use in the initial diagnosis or follow-up. The usefulness of measuring FFM with L3-targeted CT has never been evaluated in ICU patients. Therefore, the investigators aim to conduct an international multicentre prospective observational study in ICU patients to assess the prognosis value of BIA PhA at admission, and to compare the performances of BIA and L3-targeted CT for FFM measurement.

Interventions

None listed

Sponsors

University Hospital, Clermont-Ferrand
CollaboratorOTHER
Erasme University Hospital
CollaboratorOTHER
Federal University of Pelotas
CollaboratorOTHER
Clinical Hospital Centre Zagreb
CollaboratorOTHER
University Hospital, Rouen
CollaboratorOTHER
Rabin Medical Center
CollaboratorOTHER
Vilnius University
CollaboratorOTHER
Stanley Dudrick's Memorial Hospital
CollaboratorOTHER
Clinica USP Palmaplanas
CollaboratorUNKNOWN
University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* equal or more than 18 years * expected ICU length of stay of more than 48 hours * no readmission within the 48 hours following ICU discharge * no Implanted Cardiac Devices * no pregnancy or lactation * affiliated to health insurance regimen * informed consent by patient or next of kin.

Exclusion criteria

* age below 18 years * expected ICU length of stay \<48 hours * readmission within the 48 hours following ICU discharge * Implanted Cardiac Devices * pregnancy or lactation * non affiliated to health insurance regimen * no informed consent by patient or next of kin.

Design outcomes

Primary

MeasureTime frameDescription
Mortality28-day after intensive care unit admissionTo determine the impact of phase angle at ICU admission, and phase angle changes during ICU stay, on 28-day mortality

Secondary

MeasureTime frameDescription
length of mechanical ventilationday 1 to day 28 after ICU admissionTo determine the impact of phase angle, and phase angle changes during ICU stay, at ICU admission on length of mechanical ventilation.
ICU length of stayday 1 to ICU discharge or deathTo determine the impact of phase angle at ICU admission, and phase angle changes during ICU stay, on ICU length of stay.
number of nosocomial infections28 day after the intensive care unit admissionTo determine the impact of phase angle at ICU admission, and phase angle changes during ICU stay, on the number of nosocomial infections 28 day after the intensive care unit admission.
fat-free mass measurement by bioimpedance analysis and third lumbar vertebra-targeted computerized tomographyday 1 to day 28To compare bioimpedance analysis and third lumbar vertebra-targeted computerized tomography (CT) performances for fat-free mass measurement in the subgroup of patients being performed a routine abdominal CT.
ICU severity scores, APACHE II and SAPS IIwithin the 48 first hours of ICU stayDetermine the relation between phase angle mortality predicted by the ICU severity scores, APACHE II and SAPS II
hospital length of stayday 1 to hospital dischargeTo determine the impact of phase angle at ICU admission, and phase angle changes during ICU stay, on hospital length of stay.

Countries

Belgium, Brazil, Croatia, France, Israel, Lithuania, Poland, Spain, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026